Latest Articles

Publication Date
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Revisiting the role of danazol in the contemporary management of endometriosis-related pain: a systematic review.

Danazol is a synthetic steroid approved in 1976 for the treatment of endometriosis-associated pain. Despite its established efficacy, its clinical use has markedly declined due to androgenic and metabolic adverse …

Published: Aug. 28, 2026, midnight
A transcriptomics-based computational drug repurposing pipeline identifies simvastatin and primaquine as therapeutics for endometriosis.

Endometriosis has limited treatment options, prompting the search for data-driven therapeutics. We previously used a transcriptomics-based computational drug repositioning pipeline and identified several drug candidates. Fenoprofen, our top in silico …

Published: Aug. 21, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
NLRP3/Caspase-1-Mediated Pyroptosis Drives a Brain-Lesion Neuroimmune Axis in Endometriosis-Associated Pain: Molecular Mechanisms and Transcranial Direct Current Stimulation Intervention.

Background/Objectives: The NLRP3 inflammasome-Caspase-1-IL-1β pyroptotic axis participates in peripheral inflammatory responses, yet its function in peripheral-central neuroimmune crosstalk underlying endometriosis (EM)-associated pain remains unclear. This study aimed to clarify whether …

Published: July 30, 2026, midnight
Exploring New Treatment Strategies for Endometriosis-Narrative Review.

The pharmacological treatment of endometriosis using SPRMs requires improvement. The pure PR-agonist dienogest (DNG), a clinically established progestin, can serve as a reference compound for comparison. Its efficacy and safety …

Published: July 28, 2026, midnight
The Therapeutic Role of Dienogest in Endometriosis-Associated Pain: From Basics to Clinics.

The most common symptom of endometriosis is pain. The pathogenesis of endometriosis-associated pain remains unclear. In this review, we illustrate the pathogenesis of endometriosis-associated pain and the mechanisms of dienogest …

Published: July 23, 2026, midnight
GnRH Analogues for the Treatment of Endometriosis-Related Pain: A Narrative Review.

Endometriosis is a chronic estrogen-dependent condition affecting women of reproductive age and commonly presents with dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. In a substantial proportion of patients, pain persists …

Published: July 11, 2026, midnight
Managing Endometriosis-Associated Pain: A Two-Step Approach - EMJ

Managing Endometriosis-Associated Pain: A Two-Step Approach EMJ

Published: June 16, 2026, 6:33 a.m.
Endometriosis-associated Pain: Mechanism, Neuroimmune Signature, and Translational Precision Strategies.

Endometriosis affects approximately 10% of reproductive-aged women worldwide and is a leading cause of chronic pelvic pain. Despite its high prevalence and substantial socioeconomic burden, the mechanisms underlying endometriosis-associated pain …

Published: June 10, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!